


Structure-Function Analyses of the Human Gut Microbiota in Australian Subjects for Improved Risk Stratification and Clinical Management of IBD

Mark Morrison
OCE Science Leader, CSIRO Australia
Professor, The Ohio State University

National Research
FLAGSHIPS



Major sites of p-Health research activity:



Source: http://www.dragonglass.biz/a_contacts/images/MapAustralia.jpg

CSIRO Brisbane: Microbial ecology and genomics; QIMR and Mater Hospital: Colorectal cancer and IBD

CSIRO North Ryde: Theme leadership, human (epi)genetics and bioinformatics research

Royal Melbourne Hospital, Saint Vincent's Hospital and Ludwig Institute: Colorectal cancer and IBD research; proteomics and biomarker research

CSIRO Adelaide: Flagship headquarters. Human and animal trials, nutritional sciences and microbiology, biomarker research; Flinders and Queen Elizabeth Hospital: colorectal cancer and IBD research

CSIRO Flagships' research on development of resistant starches and grains:

Carcinogenesis vol.29 no.11 pp.2190–2194, 2008
doi:10.1093/carcin/bgn192
Advance Access publication August 13, 2008

Effects of high-amylose maize starch and butyrylated high-amylose maize starch on azoxymethane-induced intestinal cancer in rats

Julie M. Clarke^{1,2,*}, David L. Topping^{1,2}, Anthony R. Bird^{1,2},
Graeme P. Young^{1,3} and Lynne Cobiac⁴

¹Preventative Health National Research Flagship and ²CSIRO Human Nutrition, Adelaide, South Australia, ³Flinders Cancer Control Alliance, Flinders University, Bedford Park, South Australia and ⁴Department of Nutrition and Dietetics, School of Medicine, Flinders University, Bedford Park, South Australia

Butyrylated starch increases large bowel butyrate levels and lowers colonic smooth muscle contractility in rats

Balazs H. Bajka^{a,b}, Julie M. Clarke^a, David L. Topping^a, Lynne Cobiac^c,
Mahinda Y. Abeywardena^a, Glen S. Patten^{a,*}

^aCSIRO Preventative Health National Research Flagship, Food and Nutritional Sciences, Adelaide, South Australia 5000, Australia

^bDiscipline of Physiology, The School of Molecular & Biomedical Sciences, The University of Adelaide, South Australia 5000, Australia

^cDepartment of Nutrition and Dietetics, School of Medicine, Flinders University, South Australia 5042, Australia


Received 15 April 2010; revised 6 June 2010; accepted 7 June 2010

**Nutrition
Research**


www.njournal.com

Colorectal Cancer and Gut Health Theme – Target Rationale and Achievements

- **A multi-disciplinary approach with leading Australian clinicians and gastroenterologists.**
- Candidate Protective Food about to enter human clinical trial in CRC.
- Genes identified (and patented) for adenoma to adenocarcinoma in the human.
- Blood based protein panel identified to differentiate cancer from normal.
- Established a CRC biobank with the Ludwig Institute linked to data integration.
- Identified key drivers to increase the uptake in the national bowel screen.
- Developed a colonoscopy simulator.



Application of numerical ecology methods - Aguirre, O'Cuiv, Leggett* et al.:



The ISME Journal (2010), 1–9
© 2010 International Society for Microbial Ecology All rights reserved 1751-7362/10
www.nature.com/ismej



ORIGINAL ARTICLE

Numerical ecology validates a biogeographical distribution and gender-based effect on mucosa-associated bacteria along the human colon



Daniel Aguirre de Cárcer¹, Páraic Ó Cuív¹, Tingting Wang^{1,2}, Seungha Kang¹,
Daniel Worthley³, Vicki Whitehall³, Iain Gordon⁴ and Chris McSweeney¹, Barbara Leggett³
and Mark Morrison^{1,5}

*A collaboration with Queensland Institute of Medical Research

National Research
FLAGSHIPS



Microbial Profiling of IBD dysbiosis – Mondot, Kang, McSweeney, Leclerc*, et al.:



ORIGINAL ARTICLE

Highlighting New Phylogenetic Specificities of Crohn's Disease Microbiota

S. Mondot, PhD,* S. Kang, PhD,[†] J.P. Furet, MS,* D. Aguirre de Carcer, PhD,[†] C. McSweeney, PhD,[†] M. Morrison, PhD,[†] P. Marteau, PhD,[†] J. Doré, PhD,* and M. Leclerc, PhD*
(*Inflamm Bowel Dis* 2011;17:185–192)

Bacterial isolation and genome sequencing – O’Cuiv, Klaassens, Nelson*, Torralba*, et al.:

■ ***Enterococcus faecium* PC4.1**

- 2,811,160 bp assembled in 78 contigs
- DNA G+C = 37%
- 2739 genes

■ ***Bacteroides vulgatus* PC510**

- 4,781,702 bp assembled into 117 contigs
- DNA G+C = 42%
- 4019 genes


■ ***Enterococcus faecalis* PC1.1**

- 2,753,923 bp assembled into 79 contigs
- DNA G+C = 37%
- 2673 genes





*In collaboration with J. Craig Venter Institute, please see <http://www.hmpdacc.org>

Genome analysis of *Turicibacter* sp. PC909 – O’Cuiv, Klaassens, Nelson*, Torralba*, et al.:






*In collaboration with J. Craig Venter Institute, please see <http://www.hmpdacc.org>


De novo genome assembly from enrichment cultures using “NGS” - Bragg, Denman et al.:




Insert-size vs mid-point of mate-pair (n=25,000 pairs)




reads vs methanogen genome





“Reverse metagenomics” – from sequence data to taxonomic binning and metabolic reconstruction:



Reverse metagenomics – “culturing the unculturable” Pope, Smith et al.:




- 454 data with axenic culture
- Sanger reads recovered with Phylopythia




Moving from structure to function, transcriptomics – Klaassens, Toll, Wang*, et al.



■ *E. faecium* PC4.1



■ *B. vulgatus* PC510




CDM: Chemically defined medium
BHI: Brain Heart Infusion medium
FW: Fecal water
S: IBD patient (subject)
C: Healthy subject (control)



*Special thanks to the Chinese Scientific Council and Shanghai Jiao Tong University

Differential gene expression in fecal waters – Klaassens, Toll, Wang*, et al.:




*Special thanks to the Chinese Scientific Council and Shanghai Jiao Tong University

Collaborative clinical studies – Post-Operative Crohn's Endoscopic Recurrence (POCER) Study:


- A collaborative study with Prof. Michael Kamm (Saint Vincent's and Royal Melbourne Hospitals) and Murdoch Children's Research Institute
- Patient recruitment supported by the Australian and New Zealand IBD Consortium
- Longitudinal endoscopic monitoring of Crohn's disease post-operatively:
 - ✓ endoscopic disease progression
 - ✓ recurrent clinical symptoms &
 - ✓ need for further surgery
- Standard best drug care v endoscopy & R_x step-up
 - ✓ 1^o end-point – endoscopic recurrence at 18 months
 - ✓ 2^o end-point – clinical & surgical recurrence at 18 months

Restoration Ecology of the Anastomoses – Kang, McSweeney, Kamm*, et al.:

27 y.o. female: Low risk 3/12 metronidazole



At 6/12 Asymptomatic (CDAI 43 & CRP 5)
Rutgeert's score = i1
Step up – No






23 y.o. male: High risk 3/12 metronidazole + thiopurine



At 6/12: Asymptomatic (CDAI 5 & CRP 5)
Rutgeert's score = i4
Step up – Anti-TNF + (thiopurine)

Metagenomic analyses of biopsy μ RNA – Klaassens, de Cruz, Prideaux, Kamm*, et al.:



*In collaboration with Saint Vincent's and Royal Melbourne Hospitals, and Murdoch Children's Res. Inst.

Inflammatory Bowel Diseases (IBD) - Overview

- IBD affects ~60,000 Australians, has increased in incidence and prevalence, and increases risk of colorectal cancer.

- Improvements in risk stratification, and tailoring IBD therapy to match disease are urgently needed.

Use contemporary microbiology to generate methods for identification of IBD and intervention through changes in diet

Maximise relationship with clinical collaborators, bringing the appropriate basic science together with the clinical sciences


- Clinical collaborators / access to IBD patients
- Establish and use metagenomic methods
- Identify candidate diets and dietary interventions

Reduced impact of IBD in Australia

- Partner with industry to develop commercial products (diagnostic/diet)
- Develop and communicate diet and lifestyle advice strategies

- Diagnostic based on microbiological and gene profiling for IBD to guide therapy
- Dietary interventions that will favourably alter profiles, truncate disease and/or prolong remission

Demonstrate association of bacterial profiles with IBD and favourable shift in those profiles with dietary intervention




© CSIRO Preve National Resea

Acknowledgements:

- **INRA, Jouy-en-Josas**
 - Marion Leclerc
 - Joel Dore
 - Stanislas Mondot
- **Shanghai Jiao Tong University**
 - Liping Zhao
 - Tingting Wang
- **Murdoch Children's Res. Inst.**
 - Carl Kirkwood
 - Josef Wagner
- **J. Craig Venter Institute**
 - Karen Nelson
 - Manolito Torralba
 - A. Scott Durkin
- **University of Melbourne**
 - Finlay Macrae
- **St Vincents Hospital, Melbourne**
 - Michael Kamm
 - Peter de Cruz
 - Lani Prideaux
- **Univ. of Queensland (QIMR)**
 - Barbara Leggett
 - Vicki Whitehall
 - Daniel Worthley
- **Queen Elizabeth Hospital, Adelaide**
 - Ian Roberts-Thomson

Key CSIRO scientists:



Brisbane:

Eline Klaassens
Seungha Kang
Paraic O’Cuiv
Daniel Aguirre
Chris McSweeney

Sydney:

Caroline Kerr
Rob Dunne
Trevor Lockett

Adelaide:

Michael Conlon
Claus Christophersen
Julie Clarke
David Topping

Source: http://www.dragonglass.biz/a_contacts/images/MapAustralia.jpg

- **OCE Science Leader Program**
- **Transformational Biology Capability Platform**